BIOTECH, STOCKS, TECHNOLOGY

John McCamant

Editor,

Medical Technology Stock Letter

  • #1 Portfolio Performance of >500 by Hulbert’s Financial Digest in 2013
  • 2018 MoneyShow Top Pick MDGL up 575% ($15.96-91.79)
  • 2019 MoneyShow Top Pick MDCO up 457% ($18.57-84.90)

About John

John McCamant was named editor of the Medical Technology Stock Letter in August 2000. He has spent 35 years on the front lines of biotechnology investing as an equities analyst and in venture capital. His expertise in biotechnology investments is a subject of media interest, and he is frequently consulted and quoted by The Washington Post, BusinessWeek, Reuters, and Bloomberg.

John's Articles

Biomarin (BMRN) recently delivered solid Q3:21 total revenue of $409 million — a bit below the consensus estimate of $435 million as orders for Vimizim and Naglazyme are concentrated in the first half, notes John McCamant, biotech sector specialist and editor of The Medical Technology Stock Letter.
Vaxart (VXRT) announced that they have dosed the first subject in its Phase II COVID-19 oral tablet vaccine clinical trial which will enroll 96 subjects at four sites in the first part of its Phase II trial, notes John McCamant, biotech sector specialist and editor of The Medical Technology Stock Letter.
We haven’t discussed much on Myovant Sciences (MYOV) since way back in January when new CEO Dave Marek took over, notes John McCamant, biotech sector expert and editor of The Medical Technology Stock Letter.
We recently Zoomed with the management team at Vaxart (VXRT) to catch up and get a feel for the upcoming Phase II COVID-19 oral vaccine development, notes John McCamant, editor of The Medical technology Stock Letter — and a participant in The Interactive MoneyShow Virtual Expo on Oct. 5-7. Register here for free.

John's Videos

Covid-19 vaccines have shown the world that biotech is truly a transformative industry. Join Bioinvest's John McCamant to learn how he picks game-changing biotech stocks to super charge your portfolio.
Biotech Covid-19 vaccine development has demonstrated the power of biotech to change the world and make handsome returns for investors. With the Delta variant wrecking devastation worldwide, join this presentation to discover what's next. Can an oral vaccine be the difference maker to finally tame Covid-19?

Biotech Covid-19 vaccine development has demonstrated the power of biotech to change the world and make handsome returns for investors. With the Delta variant wrecking devastation worldwide, join this presentation to discover what's next. Can an oral vaccine be the difference maker to finally tame Covid-19?
Biotech Covid-19 vaccine development has demonstrated the power of biotech to change the world and make handsome returns for investors.



Newsletter Contributions

Medical Technology Stock Letter

The Medical Technology Stock Letter (“MTSL“) is published 24 times per year and offers unique perspectives on medical trends, portfolio companies and focus on diversification and risk management strategies to help investors profit from today’s market volatility.

Learn More